Rififylin (RFFL), another ubiquitin ligase responsible for the CFTR plasma membrane quality control (PMQC), seems to be a promising target for CF treatment because RFFL knockout mice exhibit no abnormal phenotypes [47,70]. This evidence concerns the gene RFFL and cystic fibrosis.